title: Intranasal administration of a meningococcal outer membrane vesicle vaccine induces persistent local mucosal antibodies and serum antibodies with strong bactericidal activity in humans.
abstract: A nasal vaccine, consisting of outer membrane vesicles (OMVs) from group B Neisseria meningitidis, was given to 12 volunteers in the form of nose drops or nasal spray four times at weekly intervals, with a fifth dose 5 months later. Each nasal dose consisted of 250 microg of protein, equivalent to 10 times the intramuscular dose that was administered twice with a 6-week interval to 11 other volunteers. All individuals given the nasal vaccine developed immunoglobulin A (IgA) antibody responses to OMVs in nasal secretions, and eight developed salivary IgA antibodies which persisted for at least 5 months. Intramuscular immunizations did not lead to antibody responses in the secretions. Modest increases in serum IgG antibodies were obtained in 5 volunteers who had been immunized intranasally, while 10 individuals responded strongly to the intramuscular vaccine. Both the serum and secretory antibody responses reached a maximum after two to three doses of the nasal vaccine, with no significant booster effect of the fifth dose. The pattern of serum antibody specificities against the different OMV components after intranasal immunizations was largely similar to that obtained with the intramuscular vaccine. Five and eight vaccinees in the nasal group developed persistent increases in serum bactericidal titers to the homologous meningococcal vaccine strain expressing low and high levels, respectively, of the outer membrane protein Opc. Our results indicate that meningococcal OMVs possess the structures necessary to initiate systemic as well as local mucosal immune responses when presented as a nasal vaccine. Although the serum antibody levels were less conspicuous than those after intramuscular vaccinations, the demonstration of substantial bactericidal activity indicates that a nonproliferating nasal vaccine might induce antibodies of high functional quality.
authors.affiliation: Department of Vaccinology, National Institute of Public Health, Oslo, Norway. haneberg@online.no
authors.forename: B
authors.initials: B
authors.lastname: Haneberg
authors.forename: R
authors.initials: R
authors.lastname: Dalseg
authors.forename: E
authors.initials: E
authors.lastname: Wedege
authors.forename: E A
authors.initials: EA
authors.lastname: Høiby
authors.forename: I L
authors.initials: IL
authors.lastname: Haugen
authors.forename: F
authors.initials: F
authors.lastname: Oftung
authors.forename: S R
authors.initials: SR
authors.lastname: Andersen
authors.forename: L M
authors.initials: LM
authors.lastname: Naess
authors.forename: A
authors.initials: A
authors.lastname: Aase
authors.forename: T E
authors.initials: TE
authors.lastname: Michaelsen
authors.forename: J
authors.initials: J
authors.lastname: Holst
mesh_terms: D000281:Administration, Intranasal; D000328:Adult; D000907:Antibodies, Bacterial / Q000096:biosynthesis* / Q000097:blood / Q000276:immunology; D001428:Bacterial Vaccines / Q000008:administration & dosage / Q000276:immunology*; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D018928:Immunity, Mucosal; D008297:Male; D008875:Middle Aged; D009345:Neisseria meningitidis / Q000276:immunology*
chemical_list: D000907:Antibodies, Bacterial; D001428:Bacterial Vaccines